{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:10:30Z","timestamp":1773414630164,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1136\/ard.62.5.482","type":"journal-article","created":{"date-parts":[[2003,4,14]],"date-time":"2003-04-14T15:48:42Z","timestamp":1050335322000},"page":"482-486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis"],"prefix":"10.1016","volume":"62","author":[{"given":"D","family":"Aletaha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Kapral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.62.5.482_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/art.1780300421","article-title":"Survival in rheumatoid arthritis","volume":"30","author":"Pinals","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.62.5.482_bib2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","article-title":"The mortality of rheumatoid arthritis","volume":"37","author":"Wolfe","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.62.5.482_bib3","first-page":"28","article-title":"The \u2018side effects\u2019 of rheumatoid arthritis: joint destruction, disability and early mortality","volume":"32","author":"Pincus","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.62.5.482_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.1780330103","article-title":"Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis","volume":"33","author":"Cush","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.62.5.482_bib5","first-page":"785","article-title":"The effects of some anti-inflammatory drugs on the acute-phase proteins in rheumatoid arthritis","volume":"42","author":"McConkey","year":"1973","journal-title":"Q J Med"},{"key":"10.1136\/ard.62.5.482_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJM199507203330302","article-title":"The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group","volume":"333","author":"Kirwan","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.62.5.482_bib7","series-title":"Arthritis and allied conditions: a textbook of rheumatology","first-page":"1245","article-title":"Treatment of rheumatoid arthritis","author":"Weinblatt","year":"2001"},{"key":"10.1136\/ard.62.5.482_bib8","first-page":"1885","article-title":"Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second line drugs and prednisone","volume":"19","author":"Pincus","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.62.5.482_bib9","first-page":"102","article-title":"Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis","volume":"44","author":"Fries","year":"1996","journal-title":"J Rheumatol Suppl"},{"key":"10.1136\/ard.62.5.482_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/art.1780360303","article-title":"The relative toxicity of disease-modifying antirheumatic drugs","volume":"36","author":"Fries","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.62.5.482_bib11","first-page":"188","article-title":"Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis","volume":"18","author":"Singh","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.62.5.482_bib12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.1780331001","article-title":"The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses","volume":"33","author":"Felson","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.62.5.482_bib13","first-page":"207","article-title":"Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology","volume":"26","author":"Gazarian","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.62.5.482_bib14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bmj.316.7133.716","article-title":"Hydroxychloroquine retinopathy: is screening necessary?","volume":"316","author":"Blyth","year":"1998","journal-title":"BMJ"},{"key":"10.1136\/ard.62.5.482_bib15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard.56.3.188","article-title":"Hydroxychloroquine and visual screening in a rheumatology outpatient clinic","volume":"56","author":"Grierson","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.62.5.482_bib16","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/art.1780400817","article-title":"Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice","volume":"40","author":"Levy","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.62.5.482_bib17","first-page":"1158","article-title":"Can liver test abnormalities in patients with rheumatoid arthritis be predicted by clinical symptoms?","volume":"19","author":"Singh","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.62.5.482_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1136\/ard.62.5.482_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","article-title":"Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration","volume":"43","author":"Anderson","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.62.5.482_bib20","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/rheumatology\/41.12.1367","article-title":"The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses","volume":"41","author":"Aletaha","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.62.5.482_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.62.5.482_bib22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.62.5.482_bib23","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724090186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724090186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.62.5.482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T23:35:34Z","timestamp":1737243334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724090186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["S0003496724090186"],"URL":"https:\/\/doi.org\/10.1136\/ard.62.5.482","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.62.5.482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Copyright 2003 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}